Dose individualization of carboplatin after a 120-hour infusion schedule: higher dose intensity but fewer toxicities

Therapeutic Drug Monitoring
Cédric MercierRoger Favre

Abstract

Carboplatin (CBDCA) is a widely used anticancer agent for which dose-effect and dose-toxicity relationships have been demonstrated, thus stressing the need for a controlled exposure to this drug. So far, carboplatin administration could only be individualized a priori following 2 classic methods, which are based on the evaluation of renal clearance: Calvert's and Chatelut's formulas. This study was designed to develop and evaluate the performance of an alternative CBDCA 120-hour schedule coupled to a Bayesian adaptive dosing with feedback strategy. Precision of the dosing method was assessed in 84 patients (256 courses performed during a 10-year period), by comparing CBDCA plasma concentrations observed at the end of the infusion with initial target values. A comprehensive monitoring of treatment-related toxicities also was performed. Finally, the authors compared doses actually delivered following the dose-tailoring method with the theoretical, standard, ones calculated retrospectively with Calvert's and Chatelut's formulas. No significant differences were found between experimental and theoretical concentrations. According to the target exposure chosen (3 levels), the mean doses administered to our patients were 517, 719, and...Continue Reading

References

Aug 1, 1992·American Journal of Clinical Oncology·J LokichC Moore
Oct 1, 1991·Clinical Pharmacokinetics·W J van der Vijgh
Sep 8, 1989·The Medical Letter on Drugs and Therapeutics
Nov 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A H CalvertE Wiltshaw
May 1, 1986·International Journal of Bio-medical Computing·A IliadisJ P Cano
Aug 1, 1981·Journal of Pharmacokinetics and Biopharmaceutics·L B Sheiner, S L Beal
Apr 19, 1995·Journal of the National Cancer Institute·E ChatelutR Bugat
Jan 1, 1993·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·G T BuddR M Bukowski
Oct 1, 1995·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·M J McKeage
Jan 1, 1997·Cancer Chemotherapy and Pharmacology·P GuilletR Favre
Apr 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M J JohansenR E Champlin
Jun 1, 1997·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S BénézetP Canal
May 19, 1998·Nihon Jibiinkoka Gakkai kaiho·T ShimizuK Makishima
Jun 4, 1999·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S Ghazal-AswadD R Newell
Oct 29, 1999·Journal of Cancer Research and Clinical Oncology·V R Nannan PandayJ H Beijnen
Feb 24, 2001·British Journal of Cancer·J G WrightA H Calvert
Dec 26, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A H Calvert, M J Egorin
Dec 26, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M J DooleyL K Webster
Dec 26, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·F LégerE Chatelut
May 9, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A D R HuitemaS Rodenhuis
Aug 31, 2002·Cancer Chemotherapy and Pharmacology·Milly E De JongeSjoerd Rodenhuis
Apr 26, 2003·Journal of Clinical Pharmacy and Therapeutics·S Monjanel-MouterdeA Durand
May 18, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Maja J A de JongeJaap Verweij

❮ Previous
Next ❯

Citations

Aug 22, 2013·Anti-cancer Drugs·Antonio RuggieroRiccardo Riccardi
Sep 4, 2008·Molecular Cancer Therapeutics·R Stephanie HuangM Eileen Dolan
Jun 17, 2011·Future Oncology·Kate M StamplerCharles J Dunton
Jun 12, 2013·Pharmacogenomics·Fabrice AndréGérard Milano
Aug 2, 2014·Cancer Chemotherapy and Pharmacology·Dominique BarbolosiFabrice Barlesi
Nov 26, 2015·Nature Reviews. Clinical Oncology·Dominique BarbolosiNicolas André
Jan 19, 2011·Expert Opinion on Drug Metabolism & Toxicology·Michel Adamina, Markus Joerger
Aug 20, 2009·Cancer·Michel AdaminaUlrich Guller
Jun 10, 2015·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Jessica LawrenceDavid Argyle
Nov 19, 2009·Evidence-based Complementary and Alternative Medicine : ECAM·Mei-Ling LiuChen-Jei Tai
May 25, 2016·Expert Opinion on Drug Metabolism & Toxicology·Joseph CiccoliniRaphaelle Fanciullino
Aug 12, 2010·Thérapie·Anne HulinUNKNOWN Suivi Thérapeutique Pharmacologique de la Société Française de Pharmacologie et de Thérapeutique
Jun 20, 2020·Clinical Pharmacology and Therapeutics·Florent FerrerJoseph Ciccolini
Feb 28, 2021·CPT: Pharmacometrics & Systems Pharmacology·Laure DeymeJoseph Ciccolini

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Research in Nursing & Health
Victoria A Kellogg, Donna Sullivan Havens
JAMA : the Journal of the American Medical Association
Charles L BennettDennis W Raisch
Pulmonary Pharmacology & Therapeutics
E AzambujaS S Menna Barreto
Clinics in Liver Disease
Guruprasad P Aithal, Christopher P Day
© 2022 Meta ULC. All rights reserved